| Literature DB >> 32086811 |
Tim Beltraminelli1, Michele De Palma1.
Abstract
Macrophages sustain tumour progression by facilitating angiogenesis, promoting immunosuppression, and enhancing cancer cell invasion and metastasis. They also modulate tumour response to anti-cancer therapy in pre-clinical models. This knowledge has motivated the development of agents that target tumour-associated macrophages (TAMs), some of which have been investigated in early clinical trials. Here, we provide a comprehensive overview of the biology and therapeutic targeting of TAMs, highlighting opportunities, setbacks, and new challenges that have emerged after a decade of intense translational and clinical research into these multifaceted immune cells.Entities:
Keywords: clinical trial; macrophage; monocyte; therapeutic targeting; tumour microenvironment
Year: 2020 PMID: 32086811 DOI: 10.1002/path.5403
Source DB: PubMed Journal: J Pathol ISSN: 0022-3417 Impact factor: 7.996